166
Participants
Start Date
August 22, 2016
Primary Completion Date
November 10, 2020
Study Completion Date
November 10, 2020
AIN457 (secukinumab)
"Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections."
Placebo
Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
Novartis Investigative Site, Dublin
Novartis Investigative Site, Vienna
Novartis Investigative Site, Brussels
Novartis Investigative Site, Miskolc
Novartis Investigative Site, San Miguel de Tucumán
Novartis Investigative Site, Ghent
Novartis Investigative Site, Berlin
Novartis Investigative Site, Genova
Novartis Investigative Site, Wheaton
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Montpellier
Novartis Investigative Site, Padua
Novartis Investigative Site, Guadalajara Jalisco
Novartis Investigative Site, Pisa
Novartis Investigative Site, Paris
Novartis Investigative Site, Salt Lake City
Novartis Investigative Site, Los Angeles
Novartis Investigative Site, Beverly Hills
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Boulogne-Billancourt
Novartis Investigative Site, CABA
Novartis Investigative Site, Ciudad Autonoma de Bs As
Novartis Investigative Site, Toronto
Novartis Investigative Site, Bogota
Novartis Investigative Site, Prague
Novartis Investigative Site, Mexico City
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Oslo
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Leeds
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY